Rankings
▼
Calendar
AMLX Q2 2023 Earnings — Amylyx Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena
AMLX
Amylyx Pharmaceuticals, Inc.
$1B
Q2 2023 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$98M
Gross Profit
$93M
94.3% margin
Operating Income
$20M
20.6% margin
Net Income
$22M
22.5% margin
EPS (Diluted)
$0.31
QoQ Revenue Growth
+37.5%
Cash Flow
Operating Cash Flow
$9M
Free Cash Flow
$8M
Stock-Based Comp.
$10M
Balance Sheet
Total Assets
$454M
Total Liabilities
$67M
Stockholders' Equity
$386M
Cash & Equivalents
$248M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$98M
$0
—
Gross Profit
$93M
$0
—
Operating Income
$20M
-$54M
+137.2%
Net Income
$22M
-$54M
+140.8%
← FY 2023
All Quarters
Q3 2023 →